PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/23392

Please be advised that this information was generated on 2018-01-22 and may be subject to change.
Cyclin-dependent kinases (CDKs) are key enzymes in driving cells through the cell cycle into mitosis. Their activity is tightly controlled by phosphorylation and dephosphorylation of the CDK itself and association with regulatory subunits. Binding of a specific cyclin is a prerequisite for kinase activity. On the other hand, CDK inhibitory subunits have been recently described. p21 and p27 share a region of homology, and form with CDK and cyclins ternary complexes that can inhibit a variety of CDKs (Polyak et al., 1994; Nasmyth and Hunt, 1993). p16\textsuperscript{INK4a} was the first identified member (Serrano et al., 1992) of a growing family of proteins that specifically inhibit CDK4 and CDK6 (Kamb et al., 1994; Nobori et al., 1994; Hannon and Beuth, 1994). These two CDKs act together with cyclin D to control Rb phosphorylation and passage through the starting point of the cell cycle. This is a crucial step in controlling cell growth and perturbation of this pathway is thought to be implicated in carcinogenesis (Kamb et al., 1994). Moreover, the gene encoding p16 protein, (p16\textsuperscript{INK4a}/CDKN1A/MTS1) has been recently located in the chromosomal region 9p21, a critical area of allelic loss in a wide spectrum of human tumors including bladder and kidney have been reported (Kamb et al., 1994). Interestingly, a high frequency of homozygous deletions in the p16 \textsuperscript{INK4a} gene in cell lines derived from a variety of human tumors seems to be rather low and varies in a tumour-type-dependent manner (Mori et al., 1994; Cairns et al., 1994; Spruck et al., 1994).

Here we have investigated the alterations of p16\textsuperscript{INK4a} in cell lines and primary tumours of the prostate using the polymerase chain reaction (PCR) and single-strand conformation polymorphism (SSCP) analysis.

Summary

Cyclin-dependent kinase-4 inhibitor gene (p16\textsuperscript{INK4a}) has recently been mapped to chromosome 9p21. Homozygous deletions of this gene have been found at high frequency in cell lines derived from different types of tumours. These findings suggested therefore, that p16\textsuperscript{INK4a} is a tumour-suppressor gene involved in a wide variety of human cancers. To investigate the frequency of p16\textsuperscript{INK4a} mutations/deletions in prostate cancer, we screened 20 primary prostate tumours and four established cell lines by polymerase chain reaction (PCR) and single-strand conformation polymorphism (SSCP) analysis for exon 1 and exon 2. In contrast to most previous reports, no homozygous deletions were found in prostate cancer cell lines, but one cell line (DU 145) has revealed a mutation at codon 79. Only two SSCP shifts were detected in primary tumours: one of them corresponds to a mutation at codon 55 and the other one probably corresponds to a polymorphism. These data suggest that mutation of the p16\textsuperscript{INK4a} gene is not a frequent genetic alteration implicated in prostate cancer development.

Keywords: prostate cancer; p16; mutation

Materials and methods

Patient samples, cell lines and DNA isolation

Four established prostatic cell lines (PC3, DU145, TSU/prl, LNCaP) were grown in RPMI medium containing 10% of calf serum until they reach confluency. DNA was extracted according to Miller et al. (1988). Twenty prostate cancer samples of various Gleason grades (Gg2–Gg5) were obtained by transurethral resection of the prostate, and then frozen in liquid nitrogen. Areas containing at least 70% of tumour cells as judged by step sectioning, were subjected to DNA extraction (Miller et al., 1988).

Polymerase chain reaction (PCR)

We amplified exon 1 and exon 2 for the analysis of p16\textsuperscript{INK4a} gene alterations in prostate cancer. Primer sequences used for amplification were: 5'-GAAGAAGAAGAGGGGCTG-3' and 5'-GGCGCTACCTGATTCCAAATCC-3' for exon 1. Two overlapping primer sets were taken to cover the entire 500 bp long exon 2: 5'-GACGACCAACACAGGCGTCT-3' and 5'-GAAAATTGGAACTGGAGACG-3'.

SSCP analysis

For SSCP analysis 0.3 µL [α-35S]dATP (370 MBq) were added to the reaction. Forty cycles of 50 s at 94°C, 40 s at 61°C, 40 s at 72°C were carried out in a Perkin-Elmer thermal cycler. The PCR products were subsequently analysed by electrophoresis on 2% agarose gels.

Correspondence: JA Schalken, Urological Research Laboratory, University Hospital Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.

Received 29 August 1995; revised 11 December 1995; accepted 20 December 1995.
Results and discussion

We have studied the mutation frequency in the MTS1/p16NK4 gene, in prostate cancer. Exon 1 and exon 2 represent the major part of the coding sequence (98% of the p16 protein), whereas exon 3 makes up only 11 coding nucleotides (2% of the total coding sequence). Amplification of tumour genomic DNA using primers for exon 1 and exon 2 of the p16NK4 gene resulted in bands of the predicted size 350, 240 and 340 bp respectively when separated on 2% agarose gel. A PCR product of the expected size was obtained in each of the four prostatic cell lines, indicating that none of them has a homozgyous deletion of the p16 gene.

We subsequently investigated the presence of point mutations in exon 1 and exon 2 fragments of the p16NK4 gene by SSCP analysis, a technique that is sensitive enough to detect more than 80% of mutations (Sheffield et al., 1993). The screening of almost the entire coding sequence (98%) of p16NK4 revealed band migration shifts, for exon 2, in one cell line (DU145) and two primary tumours (see example in Figure 1, sample 21).

The corresponding PCR products were sequenced. This revealed a missense mutation in DU145 at codon 76 (GAC→TAC) resulting in a change from aspartic acid to tyrosine (see example in Figure 2). The shift found in one of the primary tumours (case 166) was a mutation at codon 55 (CTG→CCG) leading to a change from leucine to proline. It remains to be determined whether the substitution of the Asp with Tyr and Leu with Pro at codons 76 and 55 respectively plays a part in prostate cancer development. The shift in the other primary tumour (case 154) corresponded to a GCG→ACG transition at codon 140 leading to a change from alanine to threonine. This change was previously reported and is thought to represent a polymorphism as it has also been found in white blood cells (Spruck et al., 1994).

Genetic aberrations involved in prostate cancer have been taken into consideration previously and partly studied. Likewise, loss of heterozygosity (LOH) studies, identifying chromosomal regions harbouring potential tumour-suppressor genes, have mainly revealed 8p, 10q, 13q, 16q and 18q (Bergerheim et al., 1991; Bova et al., 1993; Phillips et al., 1994). However, most LOH studies are limited to the analysis of a few chromosomes leaving the major part of the genome unexamined. Recently, genetic changes in primary and recurrent prostate cancer were analysed by comparative genomic hybridisation (CGH) (Visakorpi et al., 1995), a new technique enabling the survey of the entire genome for gains and losses of DNA sequences (du Manoir et al., 1993). Losses most often involved 8p (32%), 13q (32%), 6q (22%), 16q (19%), 18q (19%) and 9p (16%) (Visakorpi et al., 1995). Hence, the frequency of 9p losses seems higher than the frequency of p16 mutations we found in this study, suggesting that another gene is the major target on 9p.

At present, the role played by the p16NK4 gene in human cancer remains controversial. For instance, in a recent study using primary tumours from a variety of organ types, which were previously shown to have loss of heterozygosity involving 9p21-p22, p16 mutations were found in less than 3% (Cairns et al., 1994). Mutations within the non-coding region, rearrangement and down-regulation of p16 could play a role in the inactivation of this gene in some cases (Cheng et al., 1994). Furthermore, mutations within the promoter region may alter the normal expression of the p16 gene, although this type of mutation has not been reported to be a predominant mechanism of gene inactivation in human cancer (Cairns et al., 1994).

Using SSCP-PCR analyses on four established prostatic cell lines and 20 primary tumours, we were not able to find more than two mutations: one in the DU145 cell line, and one in primary tumours. These results indicate that mutation of the p16NK4 gene is not a frequent genetic change in the formation of primary prostate cancer. Moreover, in contrast to several reports in which homozygous deletion in cultured cell lines can reach 85% (Kamb et al., 1994), homozygous deletions in established lines of prostate cancer were not found in the four analysed cases. Parallel to our observations on primary prostatic tumours, analysis of tumours from several organs such as astrocytomas (Uckan et al., 1994), breast (Xu et al., 1994), bladder (Cairns et al., 1994; Spruck et al., 1994), lung, brain and kidney tumours (Cairns et al., 1994) revealed p16NK4 mutations in only a small fraction of primary tumours. Alternatively, higher frequencies have been found in some tumour types: 16% in head and neck squamous cell carcinoma and up to 51% in oesophageal squamous cell carcinomas have been detected recently (Mori et al., 1994). Therefore, the p16NK4 gene has certainly a key role in certain cases, but not in all tumour types.

Figure 1 A representative example of SSCP analysis of p16NK4 gene (exon 2) in primary tumour and established cell lines of the prostate. A migration shift displayed by one primary tumour (sample 21).

Figure 2 A representation of DNA sequencing of the SSCP shift observed in DU145 prostate cancer cell line. A base substitution from cytidine to adenine in the non-coding strand is indicated by an arrow. This base substitution leads to a change from guanine to thymine at codon 76 and results in an amino acid change from aspartic acid to tyrosine.
p16 mutations/deletions in prostate cancer

Y Tamimi et al

References


